World Health Organization Group I Pulmonary Hypertension: Epidemiology and Pathophysiology

Cardiology Clinics

Volumn 34, Issue 3, 2016, Pages 363-374

  Prins, Kurt W ^a   Thenappan, Thenappan ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Epidemiology; Pathophysiology; Pulmonary arterial hypertension; Pulmonary vasculature; Right ventricle

Indexed keywords

ACTIVIN RECEPTOR LIKE KINASE 1; BONE MORPHOGENETIC PROTEIN RECEPTOR 2; CAVEOLIN 1; ENDOGLIN; POTASSIUM CHANNEL; PROTEIN KCNK3; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

AEROBIC METABOLISM; AMINO ACID METABOLISM; ANAEROBIC METABOLISM; CELL METABOLISM; DISEASE REGISTRY; EXTRACELLULAR MATRIX; FATTY ACID OXIDATION; GLUCOSE METABOLISM; HEART MUSCLE ISCHEMIA; HEART RIGHT VENTRICLE FAILURE; HEART RIGHT VENTRICLE FUNCTION; HEART RIGHT VENTRICLE HYPERTROPHY; HUMAN; INCIDENCE; INFLAMMATION; LUNG ARTERY PRESSURE; LUNG BLOOD VESSEL; LUNG VASCULAR RESISTANCE; NONHUMAN; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; PULMONARY ARTERY OCCLUSION PRESSURE; PULMONARY HYPERTENSION; PULMONARY VASCULAR DISEASE; PULMONARY VASCULAR PROLIFERATION; RARE DISEASE; REVIEW; VASCULAR REMODELING; WORLD HEALTH ORGANIZATION; CLASSIFICATION; HEALTH; HYPERTENSION, PULMONARY; LUNG WEDGE PRESSURE; MORBIDITY; PHYSIOLOGY; TRENDS;

GLOBAL HEALTH; HUMANS; HYPERTENSION, PULMONARY; MORBIDITY; PULMONARY WEDGE PRESSURE; VENTRICULAR FUNCTION, RIGHT; WORLD HEALTH ORGANIZATION;

EID: 84989947749     PISSN: 07338651     EISSN: 15582264     Source Type: Journal    
DOI: 10.1016/j.ccl.2016.04.001     Document Type: Review

References (67)

1. 1 Farber, H.W., Loscalzo, J., Pulmonary arterial hypertension. N Engl J Med 351:16 (2004), 1655–1665.
2. 2 Rich, S., Dantzker, D.R., Ayres, S.M., et al. Primary pulmonary hypertension. A national prospective study. Ann Intern Med 107:2 (1987), 216–223.
3. 3 D'Alonzo, G.E., Barst, R.J., Ayres, S.M., et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 115:5 (1991), 343–349.
4. 4 Thenappan, T., Shah, S.J., Rich, S., et al. Survival in pulmonary arterial hypertension: a reappraisal of the NIH risk stratification equation. Eur Respir J 35:5 (2010), 1079–1087.
5. 5 Galiè, N., Corris, P.A., Frost, A., et al. Updated treatment algorithm of pulmonary arterial hypertension. J Am Coll Cardiol 62:25 Suppl (2013), D60–D72.
6. 6 Humbert, M., Sitbon, O., Chaouat, A., et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 173:9 (2006), 1023–1030.
7. 7 Thenappan, T., Shah, S.J., Rich, S., et al. A USA-based registry for pulmonary arterial hypertension: 1982-2006. Eur Respir J 30:6 (2007), 1103–1110.
8. 8 Badesch, D.B., Raskob, G.E., Elliott, C.G., et al. Pulmonary arterial hypertension: baseline characteristics from the REVEAL registry. Chest 137:2 (2010), 376–387.
9. 9 Ling, Y., Johnson, M.K., Kiely, D.G., et al. Changing demographics, epidemiology, and survival of incident pulmonary arterial hypertension: results from the pulmonary hypertension registry of the United Kingdom and Ireland. Am J Respir Crit Care Med 186:8 (2012), 790–796.
10. 10 Escribano-Subias, P., Blanco, I., López-Meseguer, M., et al. Survival in pulmonary hypertension in Spain: insights from the Spanish registry. Eur Respir J 40:3 (2012), 596–603.
11. 11 Hoeper, M.M., Huscher, D., Ghofrani, H.A., et al. Elderly patients diagnosed with idiopathic pulmonary arterial hypertension: results from the COMPERA registry. Int J Cardiol 168:2 (2013), 871–880.
12. 12 Zhang, R., Dai, L.Z., Xie, W.P., et al. Survival of Chinese patients with pulmonary arterial hypertension in the modern treatment era. Chest 140:2 (2011), 301–309.
13. 13 Peacock, A.J., Murphy, N.F., McMurray, J.J., et al. An epidemiological study of pulmonary arterial hypertension. Eur Respir J 30:1 (2007), 104–109.
14. 14 Jing, Z.C., Xu, X.Q., Han, Z.Y., et al. Registry and survival study in Chinese patients with idiopathic and familial pulmonary arterial hypertension. Chest 132:2 (2007), 373–379.
15. 15 Kane, G.C., Maradit-Kremers, H., Slusser, J.P., et al. Integration of clinical and hemodynamic parameters in the prediction of long-term survival in patients with pulmonary arterial hypertension. Chest 139:6 (2011), 1285–1293.
16. 16 Frost, A.E., Badesch, D.B., Barst, R.J., et al. The changing picture of patients with pulmonary arterial hypertension in the United States: how REVEAL differs from historic and non-US contemporary registries. Chest 139:1 (2011), 128–137.
17. 17 Halpern, S.D., Taichman, D.B., Misclassification of pulmonary hypertension due to reliance on pulmonary capillary wedge pressure rather than left ventricular end-diastolic pressure. Chest 136:1 (2009), 37–43.
18. 18 Thenappan, T., Shah, S.J., Gomberg-Maitland, M., et al. Clinical characteristics of pulmonary hypertension in patients with heart failure and preserved ejection fraction. Circ Heart Fail 4:3 (2011), 257–265.
19. 19 Ryan, J.J., Rich, J.D., Thiruvoipati, T., et al. Current practice for determining pulmonary capillary wedge pressure predisposes to serious errors in the classification of patients with pulmonary hypertension. Am Heart J 163:4 (2012), 589–594.
20. 20 Kovacs, G., Avian, A., Pienn, M., et al. Reading pulmonary vascular pressure tracings. How to handle the problems of zero leveling and respiratory swings. Am J Respir Crit Care Med 190:3 (2014), 252–257.
21. 21 Galiè, N., Barberà, J.A., Frost, A.E., et al. Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension. N Engl J Med 373:9 (2015), 834–844.
22. 22 McGoon, M.D., Benza, R.L., Escribano-Subias, P., et al. Pulmonary arterial hypertension: epidemiology and registries. J Am Coll Cardiol 62:25 Suppl (2013), D51–D59.
23. 23 Brown, L.M., Chen, H., Halpern, S., et al. Delay in recognition of pulmonary arterial hypertension: factors identified from the REVEAL Registry. Chest 140:1 (2011), 19–26.
24. 24 Rich, S., Pogoriler, J., Husain, A.N., et al. Long-term effects of epoprostenol on the pulmonary vasculature in idiopathic pulmonary arterial hypertension. Chest 138:5 (2010), 1234–1239.
25. 25 Ryan, J.J., Archer, S.L., The right ventricle in pulmonary arterial hypertension: disorders of metabolism, angiogenesis and adrenergic signaling in right ventricular failure. Circ Res 115:1 (2014), 176–188.
26. 26 Archer, S.L., Fang, Y.H., Ryan, J.J., et al. Metabolism and bioenergetics in the right ventricle and pulmonary vasculature in pulmonary hypertension. Pulm Circ 3:1 (2013), 144–152.
27. 27 Piao, L., Fang, Y.H., Parikh, K.S., et al. GRK2-mediated inhibition of adrenergic and dopaminergic signaling in right ventricular hypertrophy: therapeutic implications in pulmonary hypertension. Circulation 126:24 (2012), 2859–2869.
28. 28 Lowes, B.D., Minobe, W., Abraham, W.T., et al. Changes in gene expression in the intact human heart. Downregulation of alpha-myosin heavy chain in hypertrophied, failing ventricular myocardium. J Clin Invest 100:9 (1997), 2315–2324.
29. 29 Reddy, S., Bernstein, D., Molecular mechanisms of right ventricular failure. Circulation 132:18 (2015), 1734–1742.
30. 30 Vonk-Noordegraaf, A., Haddad, F., Chin, K.M., et al. Right heart adaptation to pulmonary arterial hypertension: physiology and pathobiology. J Am Coll Cardiol 62:25 Suppl (2013), D22–D33.
31. 31 Tedford, R.J., Mudd, J.O., Girgis, R.E., et al. Right ventricular dysfunction in systemic sclerosis-associated pulmonary arterial hypertension. Circ Heart Fail 6:5 (2013), 953–963.
32. 32 Drake, J.I., Gomez-Arroyo, J., Dumur, C.I., et al. Chronic carvedilol treatment partially reverses the right ventricular failure transcriptional profile in experimental pulmonary hypertension. Physiol Genomics 45:12 (2013), 449–461.
33. 33 van de Veerdonk, M.C., Kind, T., Marcus, J.T., et al. Progressive right ventricular dysfunction in patients with pulmonary arterial hypertension responding to therapy. J Am Coll Cardiol 58:24 (2011), 2511–2519.
34. 34 Tuder, R.M., Archer, S.L., Dorfmüller, P., et al. Relevant issues in the pathology and pathobiology of pulmonary hypertension. J Am Coll Cardiol 62:25 Suppl (2013), D4–D12.
35. 35 Archer, S.L., Mitochondrial dynamics–mitochondrial fission and fusion in human diseases. N Engl J Med 369:23 (2013), 2236–2251.
36. 36 Todorovich-Hunter, L., Dodo, H., Ye, C., et al. Increased pulmonary artery elastolytic activity in adult rats with monocrotaline-induced progressive hypertensive pulmonary vascular disease compared with infant rats with nonprogressive disease. Am Rev Respir Dis 146:1 (1992), 213–223.
37. 37 Maruyama, K., Ye, C.L., Woo, M., et al. Chronic hypoxic pulmonary hypertension in rats and increased elastolytic activity. Am J Physiol 261:6 Pt 2 (1991), H1716–H1726.
38. 38 Zaidi, S.H., You, X.M., Ciura, S., et al. Overexpression of the serine elastase inhibitor elafin protects transgenic mice from hypoxic pulmonary hypertension. Circulation 105:4 (2002), 516–521.
39. 39 Ilkiw, R., Todorovich-Hunter, L., Maruyama, K., et al. SC-39026, a serine elastase inhibitor, prevents muscularization of peripheral arteries, suggesting a mechanism of monocrotaline-induced pulmonary hypertension in rats. Circ Res 64:4 (1989), 814–825.
40. 40 Ye, C.L., Rabinovitch, M., Inhibition of elastolysis by SC-37698 reduces development and progression of monocrotaline pulmonary hypertension. Am J Physiol 261:4 Pt 2 (1991), H1255–H1267.
41. 41 Hassoun, P.M., Mouthon, L., Barberà, J.A., et al. Inflammation, growth factors, and pulmonary vascular remodeling. J Am Coll Cardiol 54:1 Suppl (2009), S10–S19.
42. 42 Humbert, M., Monti, G., Brenot, F., et al. Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension. Am J Respir Crit Care Med 151:5 (1995), 1628–1631.
43. 43 Soon, E., Holmes, A.M., Treacy, C.M., et al. Elevated levels of inflammatory cytokines predict survival in idiopathic and familial pulmonary arterial hypertension. Circulation 122:9 (2010), 920–927.
44. 44 Savale, L., Tu, L., Rideau, D., et al. Impact of interleukin-6 on hypoxia-induced pulmonary hypertension and lung inflammation in mice. Respir Res, 10, 2009, 6.
45. 45 Steiner, M.K., Syrkina, O.L., Kolliputi, N., et al. Interleukin-6 overexpression induces pulmonary hypertension. Circ Res 104:2 (2009), 236–244 [28p following 244].
46. 46 Taniguchi, K., Shimazaki, C., Fujimoto, Y., et al. Tocilizumab is effective for pulmonary hypertension associated with multicentric Castleman's disease. Int J Hematol 90:1 (2009), 99–102.
47. 47 Arita, Y., Sakata, Y., Sudo, T., et al. The efficacy of tocilizumab in a patient with pulmonary arterial hypertension associated with Castleman's disease. Heart Vessels 25:5 (2010), 444–447.
48. 48 Piao, L., Fang, Y.H., Parikh, K., et al. Cardiac glutaminolysis: a maladaptive cancer metabolism pathway in the right ventricle in pulmonary hypertension. J Mol Med (Berl) 91:10 (2013), 1185–1197.
49. 49 Ryan, J.J., Huston, J., Kutty, S., et al. Right ventricular adaptation and failure in pulmonary arterial hypertension. Can J Cardiol 31:4 (2015), 391–406.
50. 50 McMurtry, M.S., Bonnet, S., Wu, X., et al. Dichloroacetate prevents and reverses pulmonary hypertension by inducing pulmonary artery smooth muscle cell apoptosis. Circ Res 95:8 (2004), 830–840.
51. 51 Michelakis, E.D., McMurtry, M.S., Wu, X.C., et al. Dichloroacetate, a metabolic modulator, prevents and reverses chronic hypoxic pulmonary hypertension in rats: role of increased expression and activity of voltage-gated potassium channels. Circulation 105:2 (2002), 244–250.
52. 52 Fang, Y.H., Piao, L., Hong, Z., et al. Therapeutic inhibition of fatty acid oxidation in right ventricular hypertrophy: exploiting Randle's cycle. J Mol Med (Berl) 90:1 (2012), 31–43.
53. 53 van Wolferen, S.A., Marcus, J.T., Westerhof, N., et al. Right coronary artery flow impairment in patients with pulmonary hypertension. Eur Heart J 29:1 (2008), 120–127.
54. 54 Bogaard, H.J., Natarajan, R., Henderson, S.C., et al. Chronic pulmonary artery pressure elevation is insufficient to explain right heart failure. Circulation 120:20 (2009), 1951–1960.
55. 55 Moon, M.R., Aziz, A., Lee, A.M., et al. Differential calcium handling in two canine models of right ventricular pressure overload. J Surg Res 178:2 (2012), 554–562.
56. 56 Kögler, H., Hartmann, O., Leineweber, K., et al. Mechanical load-dependent regulation of gene expression in monocrotaline-induced right ventricular hypertrophy in the rat. Circ Res 93:3 (2003), 230–237.
57. 57 Xie, Y.P., Chen, B., Sanders, P., et al. Sildenafil prevents and reverses transverse-tubule remodeling and Ca(2+) handling dysfunction in right ventricle failure induced by pulmonary artery hypertension. Hypertension 59:2 (2012), 355–362.
58. 58 Herron, T.J., McDonald, K.S., Small amounts of alpha-myosin heavy chain isoform expression significantly increase power output of rat cardiac myocyte fragments. Circ Res 90:11 (2002), 1150–1152.
59. 59 Bakerman, P.R., Stenmark, K.R., Fisher, J.H., Alpha-skeletal actin messenger RNA increases in acute right ventricular hypertrophy. Am J Physiol 258:4 Pt 1 (1990), L173–L178.
60. 60 Tsutsui, H., Ishihara, K., Cooper, G., Cytoskeletal role in the contractile dysfunction of hypertrophied myocardium. Science 260:5108 (1993), 682–687.
61. 61 Tsutsui, H., Tagawa, H., Kent, R.L., et al. Role of microtubules in contractile dysfunction of hypertrophied cardiocytes. Circulation 90:1 (1994), 533–555.
62. 62 Stones, R., Benoist, D., Peckham, M., et al. Microtubule proliferation in right ventricular myocytes of rats with monocrotaline-induced pulmonary hypertension. J Mol Cell Cardiol 56 (2013), 91–96.
63. 63 Best, D.H., Austin, E.D., Chung, W.K., et al. Genetics of pulmonary hypertension. Curr Opin Cardiol 29:6 (2014), 520–527.
64. 64 Abdalla, S.A., Gallione, C.J., Barst, R.J., et al. Primary pulmonary hypertension in families with hereditary haemorrhagic telangiectasia. Eur Respir J 23:3 (2004), 373–377.
65. 65 Harrison, R.E., Flanagan, J.A., Sankelo, M., et al. Molecular and functional analysis identifies ALK-1 as the predominant cause of pulmonary hypertension related to hereditary haemorrhagic telangiectasia. J Med Genet 40:12 (2003), 865–871.
66. 66 Austin, E.D., Ma, L., LeDuc, C., et al. Whole exome sequencing to identify a novel gene (caveolin-1) associated with human pulmonary arterial hypertension. Circ Cardiovasc Genet 5:3 (2012), 336–343.
67. 67 Ma, L., Chung, W.K., The genetic basis of pulmonary arterial hypertension. Hum Genet 133:5 (2014), 471–479.